Arcus Biosciences, Inc.
RCUS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001724521
In the last 90 days, Arcus Biosciences, Inc. insiders filed 0 open-market purchases and 2 sales; 231 institutions reported holding it in 13F filings for Q2 2026, worth $3.78B in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Arcus Biosciences, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 130 | 1 | 131 | +2 |
| Shares | 45.2M | 12.0K | 48.3M | +3.12M (+6.9%) |
| Value | $1.24B | $330.0K | $1.68B | +$443.9M (+35.8%) |
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Arcus Biosciences, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Pictet Asset Management SA | 1,501,228 | $52.3M | 0.06% |
| Bain Capital Public Equity Management II, LLC | 454,863 | $15.9M | 0.65% |
| Granahan Investment Management Inc | 104,848 | $3.66M | 0.07% |
| HealthCor Management, L.P. | 70,050 | $2.44M | 0.11% |
| M&G Investment Management Ltd | 41,631 | $1.46M | 0.01% |
| DekaBank Deutsche Girozentrale | 38,000 | $1.31M | 0.00% |
| SG Americas Securities, LLC | 27,090 | $945.0K | 0.01% |
| Schonfeld Strategic Advisors LLC | 24,400 | $851.0K | 0.01% |
| Sante Capital Fund, LP | 24,139 | $842.0K | 0.78% |
| Jane Street Group, LLC | 22,515 | $786.0K | 0.00% |
| Ergoteles LLC | 6,600 | $230.0K | 0.01% |
| Teacher Retirement System of Texas | 6,288 | $219.0K | 0.00% |
| Amalgamated Bank | 5,925 | $207.0K | 0.00% |
| Quantbot Technologies LP | 2,000 | $69.0K | 0.01% |
| Group One Trading, L.P. | 228 | $8.00K | 0.00% |
| TCI Wealth Advisors, Inc. | 103 | $4.00K | 0.00% |
| Bell Investment Advisors, Inc | 18 | $1.00K | 0.00% |
Sold out (15)
Institutions that held Arcus Biosciences, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Renaissance Technologies LLC | 275,700 | $7.57M |
| Walleye Capital LLC | 86,438 | $2.37M |
| FIL Ltd | 36,441 | $1.00M |
| Walleye Trading LLC | 33,479 | $919.0K |
| Moore Capital Management, LP | 25,000 | $687.0K |
| Norges Bank | 20,000 | $549.0K |
| Russell Investments Group, Ltd. | 10,540 | $287.0K |
| Virginia Retirement Systems Et Al | 10,400 | $286.0K |
| Los Angeles Capital Management LLC | 10,085 | $277.0K |
| Credit Agricole S A | 6,200 | $170.0K |
| Acadian Asset Management LLC | 5,022 | $137.0K |
| FORA Capital, LLC | 4,874 | $134.0K |
| Royal Bank of Canada | 3,102 | $85.0K |
| Signaturefd, LLC | 26 | $1.00K |
| Ellevest, Inc. | 2 | $0 |
Not filed for Q3 2021 yet (1)
Institutions that held Arcus Biosciences, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Wexford Capital LP | 12,000 | $330.0K |